Endogenous molecular network reveals two mechanisms of heterogeneity within gastric cancer

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13607-13627

  Li, Site ^a   Zhu, Xiaomei ^b   Liu, Bingya ^a,c   Wang, Gaowei ^a   Ao, Ping ^a,c,d  

^a Chinese National Human Genome Center at Shanghai   (China)

^b GENMATH   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Attractor; Endogenous molecular network; Gastric cancer; Intratumor heterogeneity; Systems biology

Indexed keywords

ARTICLE; CANCER CELL; CANCER GROWTH; ENDOGENOUS MOLECULAR NETWORK; GENETIC HETEROGENEITY; HUMAN; MATHEMATICAL ANALYSIS; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NONLINEAR SYSTEM; PHENOTYPE; POSITIVE FEEDBACK; QUALITATIVE ANALYSIS; STOMACH CANCER; STOMACH EPITHELIUM; APOPTOSIS; BIOLOGICAL MODEL; GENETICS; METABOLISM; MOLECULAR DYNAMICS; PATHOLOGY; PHYSIOLOGY; STOMACH TUMOR;

APOPTOSIS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR DYNAMICS SIMULATION; STOMACH NEOPLASMS;

EID: 84931089523     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3633     Document Type: Article

References (115)

1. Danielson KG, Anderson LW, Hosick HL. Selection and characterization in culture of mammary tumor cells with distinctive growth properties in vivo. Cancer Res. 1980; 40:1812-1819.
2. Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 1978; 38:3174-3181.
3. Raz A, McLellan WL, Hart IR, Bucana CD, Hoyer LC, Sela BA, Dragsten P, Fidler IJ. Cell surface properties of B16 melanoma variants with differing metastatic potential. Cancer Res. 1980; 40:1645-1651.
4. Heppner GH, Dexter DL, DeNucci T, Miller FR, Calabresi P. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res. 1978; 38:3758-3763.
5. Barranco SC, Ho DH, Drewinko B, Romsdahl MM, Humphrey RM. Differential sensitivites of human melanoma cells grown in vitro to arabinosylcytosine. Cancer Res. 1972; 32:2733-2736.
6. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366:883-892.
7. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012; 13:e178-185.
8. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194:23-28.
9. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414:105-111.
10. Lin Y, Devin A, Rodriguez Y, Liu ZG. Cleavage of the death domain kinase RIP by caspase-8 prompts TNFinduced apoptosis. Genes Dev. 1999; 13:2514-2526.
11. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012; 12:323-334.
12. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501:338-345.
13. Junttila MR, de Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature. 2013; 501:346-354.
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
15. Grimwade D, Biondi A, Mozziconacci MJ, Hagemeijer A, Berger R, Neat M, Howe K, Dastugue N, Jansen J, Radford-Weiss I, Lo Coco F, Lessard M, Hernandez JM, Delabesse E, Head D, Liso V, et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15,17): results of the European Working Party. Groupe Francais de Cytogenetique Hematologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies". Blood. 2000; 96:1297-1308.
16. Duan Y, Nie J, Zhang Z, Zhou L, Zhu F, Zhang H, Zhu H, Shang W. A rare case with typical acute promyelocytic leukemia morphology associated with isolated isochromosome 17q without RARalpha rearrangement. Hematol Oncol Stem Cell Ther. 2013; 6:42-45.
17. Versteeg R. Cancer: Tumours outside the mutation box. Nature. 2014; 506:438-439.
18. McCarthy N. Tumour heterogeneity: the cancer kaleidoscope. Nat Rev Cancer. 2014; 14:151-152.
19. Tobal K, Saunders MJ, Grey MR, Yin JA. Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in longterm remission of acute promyelocytic leukaemia. Br J Haematol. 1995; 90:615-618.
20. McConnell MJ, Lindberg MR, Brennand KJ, Piper JC, Voet T, Cowing-Zitron C, Shumilina S, Lasken RS, Vermeesch JR, Hall IM, Gage FH. Mosaic copy number variation in human neurons. Science. 2013; 342:632-637.
21. Waddington CH. (1957). The strategy of the genes: a discussion of some aspects of theoretical biology: Allen & Unwin.
22. Kauffman SA. (1993). The Origins of Order: Self-organization and Selection in Evolution: Oxford University Press.
23. Ciliberti S, Martin OC, Wagner A. Innovation and robustness in complex regulatory gene networks. Proc Natl Acad Sci U S A. 2007; 104:13591-13596.
24. Huang S. Non-genetic heterogeneity of cells in development: more than just noise. Development. 2009; 136:3853-3862.
25. Wang G, Zhu X, Gu J and Ao P. Quantitative implementation of the endogenous molecular-cellular network hypothesis in hepatocellular carcinoma. Interface focus. 2014; 4:20130064.
26. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009; 472:467-477.
27. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009; 374:477-490.
28. Ohuchi N, Hand PH, Merlo G, Fujita J, Mariani-Costantini R, Thor A, Nose M, Callahan R, Schlom J. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization. Cancer Res. 1987; 47:1413-1420.
29. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992; 52:6735-6740.
30. Furihata C, Tatematsu M, Miki K, Katsuyama T, Sudo K, Miyagi N, Kubota T, Jin SS, Kodama K, Ito N, et al. Gastricand intestinal-type properties of human gastric cancers transplanted into nude mice. Cancer Res. 1984; 44:727-733.
31. Fiocca R, Villani L, Tenti P, Solcia E, Cornaggia M, Frigerio B, Capella C. Characterization of four main cell types in gastric cancer: foveolar, mucopeptic, intestinal columnar and goblet cells. An histopathologic, histochemical and ultrastructural study of "early" and "advanced" tumours. Pathol Res Pract. 1987; 182:308-325.
32. Tatematsu M, Ichinose M, Miki K, Hasegawa R, Kato T, Ito N. Gastric and intestinal phenotypic expression of human stomach cancers as revealed by pepsinogen immunohistochemistry and mucin histochemistry. Acta Pathol Jpn. 1990; 40:494-504.
33. Tatematsu M, Tsukamoto T, Inada K. Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci. 2003; 94:135-141.
34. Barros R, Freund JN, David L, Almeida R. Gastric intestinal metaplasia revisited: function and regulation of CDX2. Trends Mol Med. 2012; 18:555-563.
35. Camilo V, Barros R, Sousa S, Magalhaes AM, Lopes T, Mario Santos A, Pereira T, Figueiredo C, David L, Almeida R. Helicobacter pylori and the BMP pathway regulate CDX2 and SOX2 expression in gastric cells. Carcinogenesis. 2012; 33:1985-1992.
36. Shiotani A, Kamada T, Yamanaka Y, Manabe N, Kusunoki H, Hata J, Haruma K. Sonic hedgehog and CDX2 expression in the stomach. J Gastroenterol Hepatol. 2008; 23:S161-166.
37. Tsukamoto T, Inada K, Tanaka H, Mizoshita T, Mihara M, Ushijima T, Yamamura Y, Nakamura S, Tatematsu M. Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/ intestinal-mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol. 2004; 130:135-145.
38. Ao P, Galas D, Hood L, Zhu X. Cancer as robust intrinsic state of endogenous molecular-cellular network shaped by evolution. Medical hypotheses. 2008; 70:678-684.
39. Wang GW, Zhu XM, Hood L, Ao P. From Phage lambda to human cancer: endogenous molecular-cellular network hypothesis. Quantitative Biology. 2013; 1.
40. Weinberg RA. (2007). The Biology of Cancer: Garland Science.
41. Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J, Sung JJ. Dysregulation of cellular signaling in gastric cancer. Cancer Lett. 2010; 295:144-153.
42. Wang T, Fox J and Giraud A. (2009). The Biology of Gastric Cancers: Springer.
43. Ottini L, Falchetti M and Nesi G. (2012). Gene Signatures in Gastric Cancer. In: Russo A, Iacobelli S and Iovanna J, eds. Diagnostic, Prognostic and Therapeutic Value of Gene Signatures: Humana Press, pp. 95-113.
44. Freeman M. Feedback control of intercellular signalling in development. Nature. 2000; 408:313-319.
45. Kitano H. Biological robustness. Nature reviews Genetics. 2004; 5:826-837.
46. Lee L, Yin L, Zhu X, Ao P. Generic enzymatic rate equation under living conditions. J Biol Syst. 2007; 15:495-514.
47. Zhang Y, Fujita N, Tsuruo T. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene. 1999; 18:1131-1138.
48. Ao P, Galas D, Hood L, Yin L, Zhu XM. Towards predictive stochastic dynamical modeling of cancer genesis and progression. Interdiscip Sci. 2010; 2:140-144.
49. Shea MA, Ackers GK. The OR control system of bacteriophage lambda. A physical-chemical model for gene regulation. J Mol Biol. 1985; 181:211-230.
50. Krumsiek J, Polsterl S, Wittmann DM, Theis FJ. Odefy- from discrete to continuous models. BMC bioinformatics. 2010; 11:233.
51. Ferrell JE, Jr., Ha SH. Ultrasensitivity part I: Michaelian responses and zero-order ultrasensitivity. Trends Biochem Sci. 2014; 39:496-503.
52. Hill AV. The possible effects of the aggregation of the molecules of hæmoglobin on its dissociation curves. The Journal of Physiology. 1910; 40:i-vii.
53. Nash P, Tang X, Orlicky S, Chen Q, Gertler FB, Mendenhall MD, Sicheri F, Pawson T, Tyers M. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature. 2001; 414:514-521.
54. Yasuda R, Harvey CD, Zhong H, Sobczyk A, van Aelst L, Svoboda K. Supersensitive Ras activation in dendrites and spines revealed by two-photon fluorescence lifetime imaging. Nat Neurosci. 2006; 9:283-291.
55. Sprinzak D, Lakhanpal A, Lebon L, Santat LA, Fontes ME, Anderson GA, Garcia-Ojalvo J, Elowitz MB. Cisinteractions between Notch and Delta generate mutually exclusive signalling states. Nature. 2010; 465:86-90.
56. Barkai N, Leibler S. Robustness in simple biochemical networks. Nature. 1997; 387:913-917.
57. Yi TM, Huang Y, Simon MI, Doyle J. Robust perfect adaptation in bacterial chemotaxis through integral feedback control. Proc Natl Acad Sci U S A. 2000; 97:4649-4653.
58. Alon U, Surette MG, Barkai N, Leibler S. Robustness in bacterial chemotaxis. Nature. 1999; 397:168-171.
59. Eldar A, Dorfman R, Weiss D, Ashe H, Shilo BZ, Barkai N. Robustness of the BMP morphogen gradient in Drosophila embryonic patterning. Nature. 2002; 419:304-308.
60. Pe'er D, Hacohen N. Principles and strategies for developing network models in cancer. Cell. 2011; 144:864-873.
61. Ruland J. Return to homeostasis: downregulation of NF-kappaB responses. Nat Immunol. 2011; 12:709-714.
62. Loven J, Orlando DA, Sigova AA, Lin CY, Rahl PB, Burge CB, Levens DL, Lee TI, Young RA. Revisiting global gene expression analysis. Cell. 2012; 151:476-482.
63. Angeli D, Ferrell JE Jr., Sontag ED. Detection of multistability, bifurcations, and hysteresis in a large class of biological positive-feedback systems. Proc Natl Acad Sci U S A. 2004; 101:1822-1827.
64. Ingolia NT, Murray AW. Positive-feedback loops as a flexible biological module. Curr Biol. 2007; 17:668-677.
65. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010; 141:1117-1134.
66. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol. 2011; 12:104-117.
67. Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res. 2011; 17:6125-6129.
68. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol. 2011; 12:695-708.
69. Helin K. Regulation of cell proliferation by the E2F transcription factors. Curr Opin Genet Dev. 1998; 8:28-35.
70. Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013; 14:518-528.
71. Sarkar A, Hochedlinger K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell. 2013; 12:15-30.
72. Watson SA, Grabowska AM, El-Zaatari M, Takhar A. Gastrin - active participant or bystander in gastric carcinogenesis?. Nat Rev Cancer. 2006; 6:936-946.
73. Raghoebir L, Bakker ER, Mills JC, Swagemakers S, Kempen MB, Munck AB, Driegen S, Meijer D, Grosveld F, Tibboel D, Smits R, Rottier RJ. SOX2 redirects the developmental fate of the intestinal epithelium toward a premature gastric phenotype. J Mol Cell Biol. 2012; 4:377-385.
74. Tani Y, Akiyama Y, Fukamachi H, Yanagihara K, Yuasa Y. Transcription factor SOX2 up-regulates stomach-specific pepsinogen A gene expression. J Cancer Res Clin Oncol. 2007; 133:263-269.
75. Park ET, Gum JR, Kakar S, Kwon SW, Deng G, Kim YS. Aberrant expression of SOX2 upregulates MUC5AC gastric foveolar mucin in mucinous cancers of the colorectum and related lesions. Int J Cancer. 2008; 122:1253-1260.
76. Stepan V, Ramamoorthy S, Nitsche H, Zavros Y, Merchant JL, Todisco A. Regulation and function of the sonic hedgehog signal transduction pathway in isolated gastric parietal cells. J Biol Chem. 2005; 280:15700-15708.
77. Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 2000; 119:961-971.
78. van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol. 2009; 71:241-260.
79. Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, Kenji Yagi O, Saitoh K, Takeshita K, Iwai T, Yuasa Y. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett. 2002; 176:47-55.
80. Ogasawara N, Tsukamoto T, Mizoshita T, Inada K, Cao X, Takenaka Y, Joh T, Tatematsu M. Mutations and nuclear accumulation of beta-catenin correlate with intestinal phenotypic expression in human gastric cancer. Histopathology. 2006; 49:612-621.
81. Yoo NJ, Kim HS, Kim SY, Park WS, Kim SH, Lee JY, Lee SH. Stomach cancer highly expresses both initiator and effector caspases; an immunohistochemical study. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2002; 110:825-832.
82. Radulescu S, Ridgway RA, Cordero J, Athineos D, Salgueiro P, Poulsom R, Neumann J, Jung A, Patel S, Woodgett J, Barker N, Pritchard DM, Oien K, Sansom OJ. Acute WNT signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation. Oncogene. 2013; 32:2048-2057.
83. Trotta L, Bullinger E, Sepulchre R. Global analysis of dynamical decision-making models through local computation around the hidden saddle. PLoS One. 2012; 7:e33110.
84. Stock M, Otto F. Gene deregulation in gastric cancer. Gene. 2005; 360:1-19.
85. Carneiro F, Seixas M, Sobrinho-Simoes M. New elements for an updated classification of the carcinomas of the stomach. Pathol Res Pract. 1995; 191:571-584.
86. Coskun M, Troelsen JT, Nielsen OH. The role of CDX2 in intestinal homeostasis and inflammation. Biochim Biophys Acta. 2011; 1812:283-289.
87. Ramalho-Santos M, Melton DA, McMahon AP. Hedgehog signals regulate multiple aspects of gastrointestinal development. Development. 2000; 127:2763-2772.
88. Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM Jr., Azuma T, Hatakeyama M. Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene. 2007; 26:4617-4626.
89. Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res. 1999; 59:4257-4260.
90. Ebert MP, Fei G, Kahmann S, Muller O, Yu J, Sung JJ, Malfertheiner P. Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis. 2002; 23:87-91.
91. Osaki M, Kase S, Adachi K, Takeda A, Hashimoto K, Ito H. Inhibition of the PI3K-Akt signaling pathway enhances the sensitivity of Fas-mediated apoptosis in human gastric carcinoma cell line, MKN-45. J Cancer Res Clin Oncol. 2004; 130:8-14.
92. Chao X, Zao J, Xiao-Yi G, Li-Jun M, Tao S. Blocking of PI3K/AKT induces apoptosis by its effect on NF-kappaB activity in gastric carcinoma cell line SGC7901. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2010; 64:600-604.
93. Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, Qi YL, Deng Q, Cao J, Liu SQ, Luo HS, Yu JP. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer. 2008; 122:433-443.
94. Wang WQ, Zhang H, Wang HB, Sun YG, Peng ZH, Zhou G, Yang SM, Wang RQ, Fang DC. Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/ Akt signaling pathway. Molecular diagnosis & therapy. 2010; 14:155-161.
95. Kang JM, Lee BH, Kim N, Lee HS, Lee HE, Park JH, Kim JS, Jung HC, Song IS. CDX1 and CDX2 expression in intestinal metaplasia, dysplasia and gastric cancer. Journal of Korean medical science. 2011; 26:647-653.
96. Tsukamoto T, Mizoshita T, Mihara M, Tanaka H, Takenaka Y, Yamamura Y, Nakamura S, Ushijima T, Tatematsu M. Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes. Histopathology. 2005; 46:649-658.
97. Cheng XX, Sun Y, Chen XY, Zhang KL, Kong QY, Liu J, Li H. Frequent translocalization of beta-catenin in gastric cancers and its relevance to tumor progression. Oncol Rep. 2004; 11:1201-1207.
98. Ao P. Global view of bionetwork dynamics: adaptive landscape. J Genet Genomics. 2009; 36:63-73.
99. Zhu XM, Yin L, Hood L, Ao P. Calculating biological behaviors of epigenetic states in the phage lambda life cycle. Funct Integr Genomics. 2004; 4:188-195.
100. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011; 146:633-644.
101. Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, Clevers H, Jay P. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol. 2004; 166:37-47.
102. Ao P. Potential in stochastic differential equations: novel construction. Journal of physics A: mathematical and general. 2004; 37:L25.
103. Ao P, Kwon C, Qian H. On the existence of potential landscape in the evolution of complex systems. Complexity. 2007; 12:19-27.
104. Wang J, Zhang K, Xu L, Wang E. Quantifying the Waddington landscape and biological paths for development and differentiation. Proc Natl Acad Sci U S A. 2011; 108:8257-8262.
105. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014; 14:275-291.
106. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150:12-27.
107. Sasai M, Kawabata Y, Makishi K, Itoh K, Terada TP. Time scales in epigenetic dynamics and phenotypic heterogeneity of embryonic stem cells. PLoS computational biology. 2013; 9:e1003380.
108. Huang S. On the intrinsic inevitability of cancer: from foetal to fatal attraction. Semin Cancer Biol. 2011; 21:183-199.
109. Choi M, Shi J, Jung SH, Chen X, Cho KH. Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to DNA damage. Sci Signal. 2012; 5:ra83.
110. Grieco L, Calzone L, Bernard-Pierrot I, Radvanyi F, Kahn-Perles B, Thieffry D. Integrative modelling of the influence of MAPK network on cancer cell fate decision. PLoS Comput Biol. 2013; 9:e1003286.
111. Calzone L, Tournier L, Fourquet S, Thieffry D, Zhivotovsky B, Barillot E, Zinovyev A. Mathematical modelling of cell-fate decision in response to death receptor engagement. PLoS computational biology. 2010; 6:e1000702.
112. Edelman LB, Eddy JA, Price ND. In silico models of cancer. Wiley interdisciplinary reviews Systems biology and medicine. 2010; 2:438-459.
113. Cui Q, Ma Y, Jaramillo M, Bari H, Awan A, Yang S, Zhang S, Liu L, Lu M, O'Connor-McCourt M, Purisima EO, Wang E. A map of human cancer signaling. Molecular systems biology. 2007; 3:152.
114. Wu G, Feng X, Stein L. A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 2010; 11:R53.
115. Wang E, Zaman N, McGee S, Milanese J, Masoudi-Nejad A, O'Connor-McCourt M. Predictive genomics: A cancer hallmark network framework for predicting tumor clinical phenotypes using genome sequencing data. Semin Cancer Biol. 2015; 30C:4-12.